| This week's sponsor is FierceBiotech Drug Development Forum. | |  | Save 15% on the FierceBiotech 2nd Drug Development Forum
Network with 300+ biotech leaders and 100+ executive-level speakers at the largest biotech conference for optimizing pipeline strategies, partnerships and deal making September 25-27 in Boston, MA. Sign up today & save 15% w/ code C942FIERCE. |
| Welcome to FierceLifeSci Weekly Digest, your roundup of the biggest and most popular stories from each of our publications. | |
|
Featured Story | | | Tuesday, September 5, 2017 Novartis' drug-development chief, Vas Narasimhan, will take over as CEO in February 2018 from Joe Jimenez, who is retiring. Narasimhan will enjoy the fruits of Novartis' groundbreaking FDA approval of the first CAR-T treatment for cancer, but he will also be inheriting several challenges, not the least of which is pricing pressure on both branded and generic drugs. |
|
|
| This week's sponsor is Fierce Innovation Awards. | |  | Now Accepting Applications!
Apply today to the Fierce Innovation Awards! Our expert panel of judges will review submissions and determine which companies demonstrate innovative technologies and services that have the potential to make the greatest impact for biotech and pharma companies. Deadline October 20.
Apply Now! |
Top Stories Of The Week Tuesday, September 5, 2017 The FDA has placed a clinical hold on two phase 1 trials of Cellectis’ UCART123 after learning of the death of one patient. Development of the off-the-shelf CAR-T therapy is now in limbo while Cellectis works with the FDA to redesign the protocol to mitigate the risks identified in the first weeks of the trials. Thursday, September 7, 2017 Under mounting pressure in diabetes, Eli Lilly has just become the latest drugmaker to undergo a major shakeup. The pharma giant on Thursday announced plans to cut 3,500 employees by the end of the year as it shoots to achieve $500 million in annual savings. Wednesday, September 6, 2017 Merck is spending €115 million ($137 million) up front and up to €349 million in future payments to buy out German biotech Rigontec. Friday, September 1, 2017 Sanofi didn't know it would be walking into a firestorm when it teamed up with the U.S. Army to develop a Zika vaccine. But as the French drugmaker was negotiating an exclusive license on the potential product, that's just what happened—and now, the government is backing away from the collaboration. Tuesday, September 5, 2017 Most research efforts aimed at Zika virus seek to kill the pathogen. But researchers at Washington University School of Medicine in St. Louis and the University of California at San Diego are turning the anti-Zika pursuit on its head, finding a potentially useful role for the virus in treating gliobastoma. Friday, September 1, 2017 Roche’s Actemra has a new use and it’s an important one—both for the drug’s own sales and for expansion of the brand-new CAR-T market. Wednesday, September 6, 2017 Several ex-DuPont scientists let go during the American chemical giant’s recently completed megamerger with Dow Chemical have formed a nonprofit CRO, which will start operating at a new lab on Oct. 1. Tuesday, September 5, 2017 The FDA is reorganizing the way it handles manufacturing inspections, saying the new system should speed drug approvals and reduce surprises that drugmakers sometimes face when plant questions delay them. Friday, September 1, 2017 Australian smart inhaler maker Adherium has scored an FDA nod for its SmartTouch device, for use with AstraZeneca’s Symbicort aerosol inhalers. Resources Presented By: Ashfield Healthcare Join this webinar to learn how to design, deliver, and measure a successful patient support program. Presented by Nareda Mills, Ashfield's SVP of Patient Services in the US, you’ll discover how to improve adherence and improve patient outcomes using 5 key methods. |
|
